Neurodegenerative Disorders Drug Therapy Biomarkers Insight 2028

Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights.

Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights:

  • Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
  • Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
  • Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
  • Alzheimer’s Disease Insight By Classification
  • Insight On Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

Download Report Sample:

Global Parkinson Disease Drug Biomarkers Insight 2028 Report Sample

Neurodegenerative disorders are the neurological disorders which affect the neurons of human beings. These diseases possess a substantial burden on the global healthcare cost. Alzheimer disease followed by Parkinson is the major neurodegenerative diseases whose incidences are increasing at a rapid rate. Alzheimer’s disease (AD) is a progressive disorder that causes brain cells to waste away (degenerate) and die. Alzheimer’s disease is the most common cause of dementia, which is a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently. In contrast, Parkinson disease is a neurodegenerative disorder which mainly affects the parts of human brain which are critical for controlling movements, making it difficult to perform daily activities.

Although a cocktail of drugs have been granted approval for the management of neurodegenerative diseases, they are mainly used for the improving the symptoms of the diseases. The high prevalence of the disease associated with the limitations of already approved drugs has surged for the development of novel targeted therapies which can target the underlying cause of the disease. Several companies have developed targeted therapeutics for the management of neurodegenerative diseases which are present across various stages of clinical development. For instance in January 2022, Shanghai Pharmaceuticals received the approval letter from US FDA on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (marketed as GV-971), the company’s innovative drug for treating Alzheimer’s disease (AD). These rising trends in the market will foster the growth of market in the coming years.

However, high rates of failure in clinical trials and research and development have always been a major challenge in the neurodegenerative disorder therapeutics market. For instance, Aduhelm has been granted conditional approval by US FDA for the management of Alzheimer disease. However, European Commission and Ministry of Health, Labour and Welfare (MHLW) has declined to approve Aduhelm (aducanumab), saying the data from its two main clinical trials is hard to interpret, and is seeking additional data. These factors hamper the growth of the market during the forecast period. Despite this, the global neurodegenerative drug market is highly competitive. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases including Parkinson and Alzheimer disease.

As per our report findings, the global Parkinson drug market is expected to surpass US$ 8 Billion whereas global Alzheimer drug market is expected to surpass US$ 5 Billion by 2028. The major factors for the growth of the market include the rising prevalence of neurological disorders, increasing public awareness, and a strong product pipeline for neurodegenerative disease treatment. With increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. For instance, American Parkinson Disease Association, in 2020, launched a new public service announcement that encourages viewers to look closer at Parkinson’s disease. This program was featured in the national television and social media. Thus, the aforementioned factors are expected to aid in the growth of the studied market over the forecast period.

The report Global Alzheimer Drug & Parkinson Drug market provides insights into the currently approved drug class along with their mechanism of action. The report also covers the emerging therapies which are expected to enter the market in next few years. The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market. The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies. The major companies mentioned in the report include Biogen, Roche, Amneal Pharmaceuticals, Pfizer, Novartis, Sanofi, amongst others.


Preeti Dureja

Research Partner

Biomarkers Insights